Our group analyzed the relationship between predictive signature and medication in breast cancer patients and determined that paclitaxel, CDK4/6 inhibitors, and HDAC inhibitors recommended in clinical guidelines are more suitable for high-risk patients based on the IC50 values of different risk groups (Figures 11(a)–11(c)). This evidence concerns the gene CDK4 and breast carcinoma.